ELZONRIS Trademark

Trademark Overview

On Wednesday, March 21, 2018, a trademark application was filed for ELZONRIS with the United States Patent and Trademark Office. The USPTO has given the ELZONRIS trademark a serial number of 87843152. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Saturday, October 4, 2025. This trademark is owned by Stemline Therapeutics, Inc.. The ELZONRIS trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the diagnosis and treatment of cancer and auto-immune diseases; drug delivery agent in the form of infusion for the diagnosis and treatment of cancer and auto-immune diseases
elzonris

General Information

Serial Number87843152
Word MarkELZONRIS
Filing DateWednesday, March 21, 2018
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateSaturday, October 4, 2025
Registration Number5782895
Registration DateTuesday, June 18, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 12, 2019

Trademark Statements

Goods and Servicespharmaceutical preparations for the diagnosis and treatment of cancer and auto-immune diseases; drug delivery agent in the form of infusion for the diagnosis and treatment of cancer and auto-immune diseases
Translation of Words in MarkThe wording "ELZONRIS" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 28, 2018
Primary Code005
First Use Anywhere DateWednesday, January 23, 2019
First Use In Commerce DateWednesday, January 23, 2019

Trademark Owner History

Party NameStemline Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 10022
Party NameStemline Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10022
Party NameStemline Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10022

Trademark Events

Event DateEvent Description
Saturday, March 24, 2018NEW APPLICATION ENTERED
Tuesday, July 3, 2018NON-FINAL ACTION E-MAILED
Tuesday, July 3, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 12, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 7, 2019ASSIGNED TO LIE
Wednesday, March 28, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 3, 2018ASSIGNED TO EXAMINER
Tuesday, July 3, 2018NON-FINAL ACTION WRITTEN
Wednesday, December 12, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 12, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 13, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 18, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, February 18, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 23, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 9, 2019LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, February 12, 2019PUBLISHED FOR OPPOSITION
Tuesday, February 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 9, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, April 10, 2019TEAS STATEMENT OF USE RECEIVED
Wednesday, April 10, 2019USE AMENDMENT FILED
Tuesday, April 23, 2019STATEMENT OF USE PROCESSING COMPLETE
Monday, June 2, 2025TEAS SECTION 8 & 15 RECEIVED
Saturday, October 4, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Saturday, October 4, 2025REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Saturday, October 4, 2025NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Wednesday, May 15, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, May 16, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 18, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, June 18, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

elzonris auto diseases cancer immune treatment diagnosis form infusion agent drug